Allergan’s pipeline doesn’t get enough respect, if you ask Pfizer

Damian Garde

, wending toward a record-setting $ 160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry insiders.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS